Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Open accessThe DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Abstract
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not derive durable clinical benefit from these agents. Importantly, unlike other immunotherapy-responsive solid tumours, most RCCs have only a moderate mutational burden, and paradoxically, high levels of tumour CD8+ T cell infiltration are associated with a worse prognosis in patients with this disease. Building on the successes of antibodies targeting the PD-1 and CTLA4 immune checkpoints, multiple innovative immunotherapies are now in clinical development for the treatment of patients with RCC, including ICIs with novel targets, co-stimulatory pathway agonists, modified cytokines, metabolic pathway modulators, cell therapies and therapeutic vaccines. However, the successful development of such novel immune-based treatments and of immunotherapy-based combinations will require a disease-specific framework that incorporates a deep understanding of RCC immunobiology. In this Review, using the structure provided by the well-described cancer-immunity cycle, we outline the key steps required for a successful antitumour immune response in the context of RCC, and describe the development of promising new immunotherapies within the context of this framework. With this approach, we summarize and analyse the most encouraging targets of novel immune-based therapies within the RCC microenvironment, and review the landscape of emerging antigen-directed therapies for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Double-slit photoelectron interference in strong-field ionization of the neon dimer
Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07882-8 · Cited by 8,162
Double-slit photoelectron interference in strong-field ionization of the neon dimer
Kunitski, M., Eicke, N., Huber, P., Köhler, J., Zeller, S., Voigtsberger, J., Schlott, N., Henrichs, K., Sann, H., Trinter, F., et al. (2019) · Institutional Repository of Leibniz Universität Hannover (Leibniz Universität Hannover) · doi:10.15488/5174 · Cited by 8,161
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationTumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Self-citationComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Cited by
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Motzer, R. J., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Shah, A. Y., Suárez, C., Hamzaj, A., Porta, C., Hocking, C. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00290-x · Cited by 318
Self-citationThe multifaceted role of autophagy in cancer
Russell, R. C., & Guan, K. (2022) · The EMBO Journal · doi:10.15252/embj.2021110031 · Cited by 222
“Drugs that exploit this pathway block the checkpoint, often with monoclonal antibodies, and activate the anti-tumor immune response (Braun et al , 2021).”
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313906 · Cited by 189
Self-citationChoueiri, T. K., Eto, M., Motzer, R., De Giorgi, U., Buchler, T., Basappa, N. S., Méndez-Vidal, M. J., Tjulandin, S., Hoon Park, S., Melichar, B., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00049-9 · Cited by 172
Self-citation
Metadata
- Authors
- Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Institut Gustave Roussy (FR)
- Corresponding author
- Choueiri, Toni K.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-01-12
- Volume
- 18
- Issue
- 4
- Pages
- 199-214
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC8317018
- OpenAlex
- W3118419510
- Cited by
- 356
- References
- 173
- Citations by year
- 2026: 37 · 2025: 50 · 2024: 61 · 2023: 89 · 2022: 74 · 2021: 45
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA227388, P50CA101942, U01CA233100, R01CA155010, U24CA224331, P30CA006516)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- renal cell carcinoma, immune checkpoint inhibitors, cell therapy, therapeutic vaccines, tumor immune microenvironment, cancer-immunity cycle, PD-1, CTLA-4, tumor mutational burden, CD8+ T cell infiltration, immunotherapy resistance
- MeSH terms
- Immune Checkpoint Inhibitors, Carcinoma, Renal Cell, Humans, Immunologic Factors, Immunotherapy, Kidney Neoplasms, Drugs, Investigational, Therapies, Investigational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41571-020-00455-z
- The paper
- Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021). Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-020-00455-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.